 | • レポートコード：MRC-IM30893 • 出版社/出版日：IMARC / 2023年3月 • レポート形態：英文、PDF、143ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥374,850 (USD2,499) | ▷ お問い合わせ |
| Enterprisewide | ￥674,850 (USD4,499) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| グローバル調査会社のIMARC社は、2022年46億ドルであった世界のインビボ受託研究機関（CRO）市場規模が2028年には74億ドルに達し、予測期間中（2023年-2028年）、年平均8.07％成長すると予測しています。当調査資料では、インビボ受託研究機関（CRO）の世界市場を調査・分析し、序論、範囲・調査手法、エグゼクティブサマリー、イントロダクション、種類別（げっ歯、非げっ歯）分析、GLPタイプ別（非GLP、GLP毒性）分析、疾患別（自己免疫/炎症状態、疼痛管理、腫瘍、中枢神経系疾患、その他）分析、地域別（北米、アジア、欧州、中南米、中東/アフリカ）分析、SWOT分析（強み・弱み・機会・脅威）、バリューチェーン分析、ファイブフォース分析、価格分析、競争状況などの項目を掲載しています。なお、当市場の主要企業には、Charles River Laboratories International Inc.、Evotec SE、ICON plc、Iris Pharma (Abionyx Pharma)、Labcorp Drug Development (Laboratory Corporation of America Holdings)、North American Science Associates LLC、Parexel International Corporation、Pharmaceutical Product Development Inc. (Thermo Fisher Scientific Inc.)などが含まれています。 ・序論 ・範囲・調査手法 ・エグゼクティブサマリー ・イントロダクション ・世界のインビボ受託研究機関（CRO）市場規模：種類別 - げっ歯の市場規模 - 非げっ歯の市場規模 ・世界のインビボ受託研究機関（CRO）市場規模：GLPタイプ別 - 非GLPインビボ受託研究機関の市場規模 - GLP毒性インビボ受託研究機関の市場規模 ・世界のインビボ受託研究機関（CRO）市場規模：疾患別 - 自己免疫/炎症状態の市場規模 - 疼痛管理の市場規模 - 腫瘍の市場規模 - 中枢神経系疾患の市場規模 - その他疾患の市場規模 ・世界のインビボ受託研究機関（CRO）市場規模：地域別 - 北米のインビボ受託研究機関（CRO）市場規模 - アジアのインビボ受託研究機関（CRO）市場規模 - 欧州のインビボ受託研究機関（CRO）市場規模 - 中南米のインビボ受託研究機関（CRO）市場規模 - 中東/アフリカのインビボ受託研究機関（CRO）市場規模 ・SWOT分析（強み・弱み・機会・脅威） ・バリューチェーン分析 ・ファイブフォース分析 ・価格分析 ・競争状況 |
Market Overview:
The global in-vivo CRO market size reached US$ 4.6 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 7.4 Billion by 2028, exhibiting a growth rate (CAGR) of 8.07% during 2023-2028.
In-vivo contract research organizations (CROs) are institutions that conduct extensive biopharmaceutical research on a contractual basis. They support pharmaceutical and biotechnology companies in formulating effective drugs, vaccines, and medical devices by providing outsourcing services. As compared to in-vitro CRO, in-vivo CRO deals with the research performed within the living organism and conducts human clinical trials to assess the safety and efficacy of the drugs instead of organizing examinations on removed cells and tissues. They aid research institutions in managing complex medical testing, developing effective medications at minimal costs, and optimizing workflow by avoiding delays caused by hiring, fundraising, and clinical preparations. As a result, in-vivo CRO finds extensive application in pain management, oncology, and treating central nervous system (CNS) injuries and other disorders. Currently, they are bifurcated into rodent- and non-rodent-based types.
In-vivo CRO Market Trends:
The increasing prevalence of various cardiovascular ailments, especially amongst the geriatric population, and the growing need for effective medications and novel oncology-based therapies for diagnosis and treatment are primarily driving the market growth. Additionally, the rising demand for clinical-scale manufacturing of active pharmaceutical ingredients (APIs) by contract research, development, and manufacturing organizations (CRDMOs) and the shifting inclination toward biosimilars over format monoclonal antibodies are acting as other growth-inducing factors. Furthermore, the fueling health concerns have prompted biotechnology companies to engineer effective novel vaccines in collaboration with CRO, especially during the COVID-19 pandemic, which is contributing to the market growth. Moreover, the extensive utilization of in-vivo CRO to perform toxicology and pharmacokinetic studies during preclinical activities is impelling the market growth. Apart from this, the advent of bioequivalence, rapid growth in generics, ongoing patent expirations, and continuous research and development (R&D) activities to engineer personalized medicines are creating a positive outlook for the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global in-vivo CRO market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, GLP type and indication.
Breakup by Type:
Rodent
Rats
Mice
Others
Non-Rodent
Breakup by GLP Type:
Non-GLP
In House
Outsourcing
GLP Toxicology
In House
Outsourcing
Breakup by Indication:
Autoimmune/Inflammation Conditions
Rheumatoid Arthritis
Multiple Sclerosis
Osteoarthritis
Irritable Bowel Syndrome
Others
Pain Management
Chronic Pain
Acute Pain
Oncology
Blood Cancer
Solid Tumor
Others
CNS Conditions
Epilepsy
Parkinson’s Disease
Huntington’s Disease
Stroke
Traumatic Brain Injury
ALS
Muscle Regeneration
Others
Diabetes
Obesity
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Charles River Laboratories International Inc., Evotec SE, ICON plc, Iris Pharma (Abionyx Pharma), Labcorp Drug Development (Laboratory Corporation of America Holdings), North American Science Associates LLC, Parexel International Corporation, Pharmaceutical Product Development Inc. (Thermo Fisher Scientific Inc.), Pronexus Analytical AB, Syneos Health and WuXi AppTec.
Key Questions Answered in This Report:
How has the global in-vivo CRO market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global in-vivo CRO market?
What are the key regional markets?
What is the breakup of the market based on the type?
What is the breakup of the market based on the GLP type?
What is the breakup of the market based on the indication?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global in-vivo CRO market and who are the key players?
What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global In-vivo CRO Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 Rodent
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Rats
6.1.2.2 Mice
6.1.2.3 Others
6.1.3 Market Forecast
6.2 Non-Rodent
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by GLP Type
7.1 Non-GLP
7.1.1 Market Trends
7.1.2 Key Segments
7.1.2.1 In House
7.1.2.2 Outsourcing
7.1.3 Market Forecast
7.2 GLP Toxicology
7.2.1 Market Trends
7.2.2 Key Segments
7.2.2.1 In House
7.2.2.2 Outsourcing
7.2.3 Market Forecast
8 Market Breakup by Indication
8.1 Autoimmune/Inflammation Conditions
8.1.1 Market Trends
8.1.2 Key Segments
8.1.2.1 Rheumatoid Arthritis
8.1.2.2 Multiple Sclerosis
8.1.2.3 Osteoarthritis
8.1.2.4 Irritable Bowel Syndrome
8.1.2.5 Others
8.1.3 Market Forecast
8.2 Pain Management
8.2.1 Market Trends
8.2.2 Key Segments
8.2.2.1 Chronic Pain
8.2.2.2 Acute Pain
8.2.3 Market Forecast
8.3 Oncology
8.3.1 Market Trends
8.3.2 Key Segments
8.3.2.1 Blood Cancer
8.3.2.2 Solid Tumor
8.3.2.3 Others
8.3.3 Market Forecast
8.4 CNS Conditions
8.4.1 Market Trends
8.4.2 Key Segments
8.4.2.1 Epilepsy
8.4.2.2 Parkinson’s Disease
8.4.2.3 Huntington’s Disease
8.4.2.4 Stroke
8.4.2.5 Traumatic Brain Injury
8.4.2.6 ALS
8.4.2.7 Muscle Regeneration
8.4.2.8 Others
8.4.3 Market Forecast
8.5 Diabetes
8.5.1 Market Trends
8.5.2 Market Forecast
8.6 Obesity
8.6.1 Market Trends
8.6.2 Market Forecast
8.7 Others
8.7.1 Market Trends
8.7.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Charles River Laboratories International Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Evotec SE
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 ICON plc
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Iris Pharma (ABIONYX Pharma)
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.5 Labcorp Drug Development (Laboratory Corporation of America Holdings)
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 SWOT Analysis
14.3.6 North American Science Associates LLC
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.7 Parexel International Corporation
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 SWOT Analysis
14.3.8 Pharmaceutical Product Development Inc. (Thermo Fisher Scientific Inc.)
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.9 Pronexus Analytical AB
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.10 Syneos Health
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis
14.3.11 WuXi AppTec
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
Figure 2: Global: In-vivo CRO Market: Sales Value (in Billion US$), 2017-2022
Figure 3: Global: In-vivo CRO Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 4: Global: In-vivo CRO Market: Breakup by Type (in %), 2022
Figure 5: Global: In-vivo CRO Market: Breakup by GLP Type (in %), 2022
Figure 6: Global: In-vivo CRO Market: Breakup by Indication (in %), 2022
Figure 7: Global: In-vivo CRO Market: Breakup by Region (in %), 2022
Figure 8: Global: In-vivo CRO (Rodent) Market: Sales Value (in Million US$), 2017 & 2022
Figure 9: Global: In-vivo CRO (Rodent) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 10: Global: In-vivo CRO (Non-Rodent) Market: Sales Value (in Million US$), 2017 & 2022
Figure 11: Global: In-vivo CRO (Non-Rodent) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 12: Global: In-vivo CRO (Non-GLP) Market: Sales Value (in Million US$), 2017 & 2022
Figure 13: Global: In-vivo CRO (Non-GLP) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 14: Global: In-vivo CRO (GLP Toxicology) Market: Sales Value (in Million US$), 2017 & 2022
Figure 15: Global: In-vivo CRO (GLP Toxicology) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 16: Global: In-vivo CRO (Autoimmune/Inflammation Conditions) Market: Sales Value (in Million US$), 2017 & 2022
Figure 17: Global: In-vivo CRO (Autoimmune/Inflammation Conditions) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 18: Global: In-vivo CRO (Pain Management) Market: Sales Value (in Million US$), 2017 & 2022
Figure 19: Global: In-vivo CRO (Pain Management) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 20: Global: In-vivo CRO (Oncology) Market: Sales Value (in Million US$), 2017 & 2022
Figure 21: Global: In-vivo CRO (Oncology) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 22: Global: In-vivo CRO (CNS Conditions) Market: Sales Value (in Million US$), 2017 & 2022
Figure 23: Global: In-vivo CRO (CNS Conditions) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 24: Global: In-vivo CRO (Diabetes) Market: Sales Value (in Million US$), 2017 & 2022
Figure 25: Global: In-vivo CRO (Diabetes) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 26: Global: In-vivo CRO (Obesity) Market: Sales Value (in Million US$), 2017 & 2022
Figure 27: Global: In-vivo CRO (Obesity) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 28: Global: In-vivo CRO (Other Indications) Market: Sales Value (in Million US$), 2017 & 2022
Figure 29: Global: In-vivo CRO (Other Indications) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 30: North America: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 31: North America: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 32: United States: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 33: United States: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 34: Canada: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 35: Canada: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 36: Asia-Pacific: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 37: Asia-Pacific: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 38: China: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 39: China: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 40: Japan: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 41: Japan: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 42: India: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 43: India: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 44: South Korea: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 45: South Korea: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 46: Australia: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 47: Australia: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 48: Indonesia: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 49: Indonesia: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 50: Others: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 51: Others: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 52: Europe: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 53: Europe: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 54: Germany: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 55: Germany: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 56: France: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 57: France: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 58: United Kingdom: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 59: United Kingdom: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 60: Italy: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 61: Italy: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 62: Spain: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 63: Spain: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 64: Russia: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 65: Russia: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 66: Others: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 67: Others: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 68: Latin America: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 69: Latin America: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 70: Brazil: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 71: Brazil: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 72: Mexico: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 73: Mexico: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 74: Others: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 75: Others: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 76: Middle East and Africa: In-vivo CRO Market: Sales Value (in Million US$), 2017 & 2022
Figure 77: Middle East and Africa: In-vivo CRO Market: Breakup by Country (in %), 2022
Figure 78: Middle East and Africa: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 79: Global: In-vivo CRO Industry: SWOT Analysis
Figure 80: Global: In-vivo CRO Industry: Value Chain Analysis
Figure 81: Global: In-vivo CRO Industry: Porter's Five Forces Analysis